151 related articles for article (PubMed ID: 22508239)
21. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
Rastelli AL; Taylor ME; Gao F; Armamento-Villareal R; Jamalabadi-Majidi S; Napoli N; Ellis MJ
Breast Cancer Res Treat; 2011 Aug; 129(1):107-16. PubMed ID: 21691817
[TBL] [Abstract][Full Text] [Related]
22. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.
Santa-Maria CA; Bardia A; Blackford AL; Snyder C; Connolly RM; Fetting JH; Hayes DF; Jeter SC; Miller RS; Nguyen A; Quinlan K; Rosner GL; Slater S; Storniolo AM; Wolff AC; Zorzi J; Henry NL; Stearns V
Breast Cancer Res Treat; 2018 Aug; 171(1):121-129. PubMed ID: 29752687
[TBL] [Abstract][Full Text] [Related]
23. Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy.
Li H; Sereika SM; Marsland AL; Conley YP; Bender CM
J Clin Nurs; 2019 Dec; 28(23-24):4560-4571. PubMed ID: 31469461
[TBL] [Abstract][Full Text] [Related]
24. A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study.
Martínez N; Herrera M; Frías L; Provencio M; Pérez-Carrión R; Díaz V; Morse M; Crespo MC
Clin Transl Oncol; 2019 Apr; 21(4):489-498. PubMed ID: 30293230
[TBL] [Abstract][Full Text] [Related]
25. Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial.
Prasad C; Greenspan SL; Vujevich KT; Brufsky A; Lembersky BC; van Londen GJ; Jankowitz RC; Puhalla SL; Rastogi P; Perera S
Bone; 2016 Sep; 90():123-6. PubMed ID: 27018037
[TBL] [Abstract][Full Text] [Related]
26. Changes in Vertebral Marrow Fat Fraction Using 3D Fat Analysis & Calculation Technique Imaging Sequence in Aromatase Inhibitor-Treated Breast Cancer Women.
Wan T; Zhu Y; Han Q; Liu L
Front Endocrinol (Lausanne); 2022; 13():931231. PubMed ID: 35813643
[TBL] [Abstract][Full Text] [Related]
27. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.
Henry NL; Giles JT; Ang D; Mohan M; Dadabhoy D; Robarge J; Hayden J; Lemler S; Shahverdi K; Powers P; Li L; Flockhart D; Stearns V; Hayes DF; Storniolo AM; Clauw DJ
Breast Cancer Res Treat; 2008 Sep; 111(2):365-72. PubMed ID: 17922185
[TBL] [Abstract][Full Text] [Related]
28. Aromatase inhibitors associated musculoskeletal disorders and bone fractures in postmenopausal breast cancer patients: a result from Chinese population.
Xu L; Wang J; Xue DD; He W
Med Oncol; 2014 Sep; 31(9):128. PubMed ID: 25056205
[TBL] [Abstract][Full Text] [Related]
29. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
Lintermans A; Van Asten K; Jongen L; Van Brussel T; Laenen A; Verhaeghe J; Vanderschueren D; Lambrechts D; Neven P
Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969
[TBL] [Abstract][Full Text] [Related]
30. Living with chronic pain: perceptions of breast cancer survivors.
Bao T; Seidman A; Li Q; Seluzicki C; Blinder V; Meghani SH; Farrar JT; Mao JJ
Breast Cancer Res Treat; 2018 May; 169(1):133-140. PubMed ID: 29350307
[TBL] [Abstract][Full Text] [Related]
31. Effect of Jianpi Bushen formula on aromatase-inhibitor-associated bone loss after menopause.
Dai Y; Chen Q; Guan R; Xu R; Qiu C; Song X; Guo Q; Wang Z; Chen Q; Wang Z
J Tradit Chin Med; 2018 Dec; 38(6):879-889. PubMed ID: 32186135
[TBL] [Abstract][Full Text] [Related]
32. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
[TBL] [Abstract][Full Text] [Related]
33. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
[TBL] [Abstract][Full Text] [Related]
34. Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients.
Crew KD; Capodice JL; Greenlee H; Apollo A; Jacobson JS; Raptis G; Blozie K; Sierra A; Hershman DL
J Cancer Surviv; 2007 Dec; 1(4):283-91. PubMed ID: 18648963
[TBL] [Abstract][Full Text] [Related]
35. [Prevention and treatment of aromatase inhibitor-associated bone loss by shugan jiangu recipe in postmenopausal women with breast cancer: a clinical study].
Li YQ; Sun H; Xue D; Xu YC; Li ZD; Wang W; Li PP
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Sep; 34(9):1064-8. PubMed ID: 25335329
[TBL] [Abstract][Full Text] [Related]
36. Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors.
Spangler L; Yu O; Loggers E; Boudreau DM
J Womens Health (Larchmt); 2013 Feb; 22(2):132-40. PubMed ID: 23362883
[TBL] [Abstract][Full Text] [Related]
37. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
[TBL] [Abstract][Full Text] [Related]
38. Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study.
Pedersini R; Monteverdi S; Mazziotti G; Amoroso V; Roca E; Maffezzoni F; Vassalli L; Rodella F; Formenti AM; Frara S; Maroldi R; Berruti A; Simoncini E; Giustina A
Bone; 2017 Apr; 97():147-152. PubMed ID: 28104509
[TBL] [Abstract][Full Text] [Related]
39. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
Cepa M; Vaz C
Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
[TBL] [Abstract][Full Text] [Related]
40. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
Santen RJ
J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
